Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and
zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have …

Objective To develop an evidence-based guideline to help clinicians make decisions about
when and how to safely taper and stop antipsychotics; to focus on the highest level of …

Objective: Pharmacological options for treating bipolar disorder have increased over the
past 20 years, with several second-generation antipsychotics receiving regulatory approval …

Introduction: New antipsychotics continuously arrive on the market, which thereby influences
the approved and off-label prescribing (OLP) schemes. We aimed to identify the recent …

This British Association for Psychopharmacology guideline replaces the original version
published in 2010, and contains updated information and recommendations. A consensus …

Prescription rates of second-generation antipsychotics (SGAs) are rapidly increasing for non-
indicated (ie, off-label) usage. SGAs used for approved indications are associated with …

Background Long-term sedative use is prevalent and associated with significant morbidity,
including adverse events such as falls, cognitive impairment, and sedation. The …

Background The impact of long-term lithium treatment on weight gain has been a
controversial topic with conflicting evidence. We aim to assess reporting of weight gain …

Background Observational evidence suggests that atypical antipsychotics such as
quetiapine are increasingly being used to manage insomnia. This is concerning given the …

Objective The objective was to compare, in a real‐world setting, the risk of mental and
physical health events associated with different antipsychotic drugs (clozapine, olanzapine …